CN1077886A - 药用的7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并嗪-6-甲酸类及其酯 - Google Patents
药用的7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并嗪-6-甲酸类及其酯 Download PDFInfo
- Publication number
- CN1077886A CN1077886A CN93103503A CN93103503A CN1077886A CN 1077886 A CN1077886 A CN 1077886A CN 93103503 A CN93103503 A CN 93103503A CN 93103503 A CN93103503 A CN 93103503A CN 1077886 A CN1077886 A CN 1077886A
- Authority
- CN
- China
- Prior art keywords
- pyrido
- fluoro
- oxo
- benzoxazinyl
- methyl isophthalic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002148 esters Chemical class 0.000 title abstract description 4
- UJEJXGQFNRATQB-UHFFFAOYSA-N C1=COC2=CC=CC3=C2N1C=C(C(=O)O)C3=O Chemical class C1=COC2=CC=CC3=C2N1C=C(C(=O)O)C3=O UJEJXGQFNRATQB-UHFFFAOYSA-N 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 32
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000002672 hepatitis B Diseases 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- XNIVKSPSCYJKBL-UHFFFAOYSA-N 2h-1,2-benzoxazine-6-carboxylic acid Chemical class O1NC=CC2=CC(C(=O)O)=CC=C21 XNIVKSPSCYJKBL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- -1 fluoro-4H-quinoline-3-formic acid Chemical compound 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000035126 Facies Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- ZEOVXNVKXIPWMS-UHFFFAOYSA-N 2,2-dichloropropane Chemical compound CC(C)(Cl)Cl ZEOVXNVKXIPWMS-UHFFFAOYSA-N 0.000 description 1
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
本发明涉及将已知的7-氧代-7H-吡啶并(1,2,
3-de)-(1,4)苯并嗪-6-甲酸类及其酯用作抗病毒
活性药物。
Description
本发明涉及已知的7-氧代-7H-吡啶并〔1,2,3-de〕〔1,4〕苯并噁嗪-6-甲酸类及其酯作为抗病毒活性药物的用途。
本发明采用的化合物是已知的(参见EP-A-253,235),它们或者作为抗病毒的活性化合物,或者作为制备所述活性化合物的中间体。
本发明惊奇地发现下列化合物具有很强的抗病毒活性,因此适合用于战胜病毒性疾病,尤其是B型肝炎,所述化合物是:
9,10-二氟-3-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(3-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9,10-二氟-2-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯;
9,10-二氟-2-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-2-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9,10-二氟-7-氧代-2-苯基-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯;
9,10-二氟-7-氧代2-苯基-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;和
6,7-二氟-9-氧代-9H-环己烷并〔1,2-b〕吡啶并〔1′,2′,3-de〕-〔1,4〕苯并噁嗪-10-甲酸乙酯。
用于战胜病毒性疾病,特别是B型肝炎的优选化合物是:
9-氟-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(3-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-2-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9,10-二氟-2-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯;
9,10-二氟-7-氧代-2-苯基-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯;和
9,10-二氟-7-氧代-2-苯基-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸。
用于战胜病毒性疾病,特别是B型肝炎的特别优选的化合物是
9-氟-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(3-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;和
9,10-二氟-2-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯。
上面列出的本发明化合物可按EP-A-253,235中公开的方法制备。
活性的证明是在用B型肝炎病毒DNA转染的肝细胞瘤细胞(HEP G2.2.15)中进行的。用下述文献中描述的HBV试验系统得到了下列实例的结果:
[Sells,M.A.;Chen,M.L.,Acs,G.,Proc.Natl.Acad.Sci.USApp.1005-1009,vol.84(1987)]:
将转染的肝细胞瘤细胞(HEP G2.2.15)与不同浓度的具体化合物一起孵化。如同可证明HBsAg的浓度降低一样,通过用本发明化合物处理转染的肝细胞瘤细胞系HEP G2.2.15,可证明在上清液中出现病毒专一的HBV DNA,用PEG沉淀后测定细胞培养的上清液中HBV DNA的含量。应用未放射标记的HBV基因组的DNA样品影响上述的测定。参见下述文献:
[Pauly,P.,1982,Ph.D.thesis,University of G
ttingen,F.R.G.;K
chel et al.,1990,EMBL,Accession No.X 51790].
已观察到细胞外HBV-DNA减少和HBV专一的复制中间体的数量降低。同时用商购的Elisa试验可证明对HBsAg形成的影响。IC50值涉及底物的浓度,该浓度在上述试验条件下产生上清液中HBV DNA浓度的50%抑制。
表A
实施例号 | IC50(μM) | SI |
2346 | 10-0.10.10.5 | -5>10050-100 |
同时,通过用结晶紫染色或通过将放射标记的胸苷掺入细胞的DNA中,可进行可能存在的本发明化合物的任何细胞毒作用的测定。
通过与HEL细胞和MEF细胞一起孵化可试验本发明化合物对其它细胞的影响。在高达250μM浓度下未观察到对这些细胞活力的影响。
作为本发明可应用的化合物的适应症范围的实例,可提及的是:
可导致肝炎的急性和慢性病毒感染(如肝炎病毒感染)的治疗;以及疱疹病毒Ⅰ型和Ⅱ型、巨细胞病毒、水痘一带疱疹病毒和HIV的病毒感染的治疗。
特别优选的是对慢性B型肝炎病毒感染的治疗和急性B型肝炎病毒感染的治疗。
本发明包括含有一种或多种本发明化合物及无毒的、药学上适用的惰性赋形剂或由它们构成的药物制剂,及制备这些药物制剂的方法。
在上述的药物制剂中,本发明的活性化合物最好以占混合物总重量的约0.1-99.5%,优选约0.5-99.5%的量存在。
除本发明化合物外,上述的药物制剂还可含有其它药用活性化合物。
按常规方法,例如将活性成分与赋形剂混合,可进行上述药物制剂的生产。
为了达到理想的结果,通常已发现:在人和兽药中,最好以每24小时约0.5至500mg/Kg体重,优选1至100mg/Kg体重的总量,分数个单剂量施用本发明活性化合物。每一单剂量最好含活性化合物约1-80mg/Kg体重,特别是1-30mg/Kg体重。然而,必要时可偏离上述的剂量,具体地取决于病人的情况和体重、疾病的性质和严重程度、制剂的类型和给药方式、以及给药的时间和间隔。
原料化合物
实施例Ⅰ
3-(1,1-二甲氧基-2-丙氨基)-2-(2,3,4,5-四氟苯甲酰基)-丙烯酸乙酯
将6.4g3-乙氧基-2-(2,3,4,5-四氟苯甲酰基)-丙烯酸乙酯加入8ml乙醇中,在冰冷却下滴入1-氨基丙炔醛缩二甲醇(2.6g)的乙醇(15ml)溶液,升至室温,搅拌2小时,真空浓缩。得8g油。
实施例Ⅱ
1-(1,1-二甲氧基-2-丙基)-4-氧代-6,7,8-三氟-4H-喹啉-3-甲酸乙酯
将64g实施例Ⅰ的粗产物和24gK2CO3于370mlDMF中在140℃加热4小时后倒于冰上,沉淀溶入CH2CL2中,洗有机相,用Na2SO4干燥,真空浓缩后得50g油性固体,用乙醚洗纯化。得42g产物,m.p.125-126℃。
实施例Ⅲ
4-氧代-1-(1-氧代-2-丙基)-6,7,8-三氟-4H-喹啉-3-甲酸
将4.4g实施例Ⅱ产物与15ml乙酸、13ml水和1.3ml硫酸一起于140℃加热4小时,冷至室温后加水,分离沉淀出的固体。产物:3.0g;m.p.188-190℃(分解)。
实施例Ⅳ
2-(2,3,4,5-四氟苯甲酰基)-3-(2,2-二甲氧基-乙氨基)-丙烯酸乙酯
按类似于实施例Ⅰ的方法,将3-乙氧基-2-(2,3,4,5-四氟苯甲酰基)-丙烯酸乙酯与氨基乙醛缩二甲醇反应,得标题化合物(油)。
实施例Ⅴ
1-(2,2-二甲氧基乙基)-4-氧代-6,7,8-三氟-4H-喹啉-3-甲酸乙酯
按类似于实施例Ⅱ的反应,进行实施例Ⅳ产物的环化,得标题化合物,m.p.104-106℃。
实施例Ⅵ
1,4-二氢-4-氧代-1-(2-氧代乙基)-6,7,8-三氟-4H-喹啉-3-甲酸
按类似于实施例Ⅲ的方法,水解实施例Ⅴ的产物,得标题化合物,m.p.220-222℃。
制备实例
实施例1
9,10-二氟-3-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸
将2.2g实施例Ⅲ产物和0.6gNaOH在20ml水和20ml乙醇中的混合物一起沸腾4小时,冷至室温,用稀盐酸酸化,分离得到的固体,得1.8g产物,m.p.248-250℃(分解)。
实施例2
9-氟-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸
将1.6g实施例1产物和2.9gN-甲基哌嗪于20mlDMSO中在140℃加热2.5小时,冷却后高真空浓缩,残余物与水混合,分离出沉淀,于50℃真空干燥,得0.4g产物,m.p.262-263℃(分解)。
按类似于实施例2的方法,制备了表1中所列的化合物。
实施例5
9-氟-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸
将2.85g4-氧代-1-(2-氧代乙基)-6,7,8-三氟-4H-喹啉-3-甲酸和5.0gN-甲基哌嗪在30mlDMSO中于140℃加热2.5小时,然后高真空除去所有的挥发物,残余物在搅拌下与乙腈混合,分离出固体,干燥,得2.6g产物,m.p.>300℃。
实施例6
9,10-二氟-2-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯
将5g 6,7,8-三氟-4-羟基-3-喹啉甲酸乙酯、3.5g氯代丙酮和6.6gK2CO3在40mlDMF中于90℃加热10小时,冷却,真空除去所有挥发物,残余物与水一起搅拌,分离出固体,干燥,于DMF中重结晶,得3.4g产物,m.p.229-230℃。
实施例7
9,10-二氟-2-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸
按类似于实施例6的方法,得到标题化合物,2.4g,m.p.>300℃。
实施例8
9-氟-2-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸
将2.4g实施例7产物和4.3gN-甲基哌嗪在25mlDMSO中于140℃加热2.5小时,真空除去所有挥发物,残余物用水一起搅拌,分离固体,干燥,得1.3g产物,m.p.255-256℃(分解)。
实施例9
9,10-二氟-7-氧代2-苯基-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯
将5g6,7,8-三氟-4-羟基-3-喹啉甲酸乙酯、5.9gω-氯代乙酰苯和6.6gK2CO3在40mlDMF中于90℃加热10小时,然后真空浓缩,残余物与水一起搅拌,分离固体,于DMF中重结晶,得2.4g产物,m.p.251-252℃。
实施例10
9,10-二氟-7-氧代2-苯基-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸
将1.9g实施例9产物、6ml乙酸、4ml水和0.5ml硫酸沸腾4小时,用水稀释,分离出固体,得1.7g产物,m.p.>300℃。
实施例11
6,7-二氟-9-氧代-9H-环己烷并〔1,2-b〕吡啶并〔1′,2′,3-de〕-〔1,4〕苯并噁嗪-10-甲酸乙酯
将5g6,7,8-三氟-4-羟基-3-喹啉甲酸乙酯、5g2-氯代环己酮和6.6gK2CO3在40mlDMF中于90℃加热10小时后真空浓缩,残余物溶入水中,用CH2CL2提取,有机相干燥并蒸发浓缩,残余物通过柱色谱(硅胶;洗脱液:甲苯/乙酸乙酯1∶1)分离,得0.6g产物,m.p.198-208℃。
Claims (8)
1、战胜病毒性疾病的下列化合物:
9,10-二氟-3-甲基-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(3-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸;
9-氟-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸;
9,10-二氟-2-甲基-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸乙酯;
9,10-二氟-2-甲基-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸;
9-氟-2-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸;
9,10-二氟-7-氧代-2-苯基-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸乙酯;
9,10-二氟-7-氧代-2-苯基-7H-吡啶并[1,2,3-de]-[1,4]苯并噁嗪-6-甲酸;和
6,7-二氟-9-氧代-9H-环己烷并[1,2-b]吡啶并[1′,2′,3-de]-[1,4]苯并噁嗪-10-甲酸乙酯。
2、战胜病毒性疾病的下列化合物:
9-氟-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(3-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-2-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9,10-二氟-2-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯;
9,10-二氟-7-氧代-2-苯基-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯;和
9,10-二氟-7-氧代-2-苯基-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸。
3、战胜病毒性疾病的下列化合物:
9-氟-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;
9-氟-3-甲基-10-(3-甲基-1-哌嗪基)-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸;和
9,10-二氟-2-甲基-7-氧代-7H-吡啶并〔1,2,3-de〕-〔1,4〕苯并噁嗪-6-甲酸乙酯。
4、权利要求1至3的化合物,用于战胜B型肝炎。
5、权利要求1至3的化合物用于制备抗病毒药物。
6、权利要求1至3的化合物用于制备战胜B型肝炎的药物。
7、含有至少一种权利要求1至3的化合物的抗病毒剂。
8、含有至少一种权利要求1至3的化合物以战胜B型肝炎的药物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4210939.6 | 1992-04-02 | ||
DE4210939A DE4210939A1 (de) | 1992-04-02 | 1992-04-02 | Verwendung von 7-Oxo-7H-pyrido[1,2,3-de][1,4]benzoxacin-6-carbonsäuren und -estern als Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1077886A true CN1077886A (zh) | 1993-11-03 |
Family
ID=6455791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93103503A Pending CN1077886A (zh) | 1992-04-02 | 1993-04-02 | 药用的7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并嗪-6-甲酸类及其酯 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0563733A1 (zh) |
JP (1) | JPH0616560A (zh) |
KR (1) | KR930021208A (zh) |
CN (1) | CN1077886A (zh) |
AU (1) | AU3569193A (zh) |
CA (1) | CA2093106A1 (zh) |
DE (1) | DE4210939A1 (zh) |
HU (1) | HU9300925D0 (zh) |
IL (1) | IL105229A0 (zh) |
MX (1) | MX9301667A (zh) |
NO (1) | NO931009L (zh) |
PL (1) | PL298321A1 (zh) |
ZA (1) | ZA932349B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100333764B1 (ko) * | 1999-09-03 | 2002-04-25 | 신영균 | 아크스폿 용접용 보조장치 |
AR048650A1 (es) * | 2004-05-04 | 2006-05-10 | Tibotec Pharm Ltd | Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih |
AR056652A1 (es) * | 2005-04-11 | 2007-10-17 | Tibotec Pharm Ltd | Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento |
KR20060093321A (ko) * | 2006-08-05 | 2006-08-24 | 박장용 | 와이어 송급 장치에서 크레이터를 설정할 수 있는 용접기시스템 |
CN102260277B (zh) * | 2010-05-24 | 2013-07-24 | 中国科学院上海药物研究所 | 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3623757A1 (de) * | 1986-07-15 | 1988-01-21 | Bayer Ag | Neue 1,8-verbrueckte 4-chinoloncarbonsaeuren und diese enthaltende arzneimittel |
-
1992
- 1992-04-02 DE DE4210939A patent/DE4210939A1/de not_active Withdrawn
-
1993
- 1993-03-19 NO NO93931009A patent/NO931009L/no unknown
- 1993-03-22 EP EP93104661A patent/EP0563733A1/de not_active Withdrawn
- 1993-03-23 KR KR1019930004470A patent/KR930021208A/ko not_active Application Discontinuation
- 1993-03-25 MX MX9301667A patent/MX9301667A/es unknown
- 1993-03-30 HU HU9300925A patent/HU9300925D0/hu unknown
- 1993-03-30 CA CA002093106A patent/CA2093106A1/en not_active Abandoned
- 1993-03-31 PL PL29832193A patent/PL298321A1/xx unknown
- 1993-03-31 IL IL105229A patent/IL105229A0/xx unknown
- 1993-04-01 ZA ZA932349A patent/ZA932349B/xx unknown
- 1993-04-01 JP JP5096508A patent/JPH0616560A/ja active Pending
- 1993-04-02 CN CN93103503A patent/CN1077886A/zh active Pending
- 1993-04-02 AU AU35691/93A patent/AU3569193A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2093106A1 (en) | 1993-10-03 |
KR930021208A (ko) | 1993-11-22 |
NO931009L (no) | 1993-10-04 |
PL298321A1 (en) | 1993-10-04 |
EP0563733A1 (de) | 1993-10-06 |
MX9301667A (es) | 1993-11-01 |
NO931009D0 (no) | 1993-03-19 |
ZA932349B (en) | 1994-10-03 |
AU3569193A (en) | 1993-10-07 |
HU9300925D0 (en) | 1993-06-28 |
DE4210939A1 (de) | 1993-10-07 |
IL105229A0 (en) | 1993-07-08 |
JPH0616560A (ja) | 1994-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200276198A1 (en) | Combination therapy of an hbv capsid assembly inhibitor and an interferon | |
CN1044089C (zh) | 以对映体纯β-D-二氧戊环核苷为活性成分的药物组合物 | |
JP7101663B2 (ja) | Tlr7アゴニストとhbvキャプシドアセンブリ阻害剤の併用療法 | |
WO2018087345A1 (en) | COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON | |
JPH05202045A (ja) | 肝炎の処置に有用な1,3−オキサチオラン | |
KR20050053709A (ko) | Hcv 세린 프로테아제의 강력한 억제제 | |
US20160346287A1 (en) | Method of treating viral infections | |
CN1147766A (zh) | 治疗感染的药物 | |
US20230076319A1 (en) | Inhibitors of hepatitis b virus | |
CN1077886A (zh) | 药用的7-氧代-7H-吡啶并[1,2,3-de]-[1,4]苯并嗪-6-甲酸类及其酯 | |
CN109364074B (zh) | 6-氨基烟酰胺作为有效成分在制备乙型肝炎治疗药物中的用途 | |
CN1331597A (zh) | 双膦酸酯用于预防和治疗传染性病变的用途 | |
CN1483731A (zh) | 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用 | |
CN1712408A (zh) | 双环醇糖苷类化合物及其制备方法和用途 | |
CN1164855A (zh) | 含有连接碳环的取代苯并咪唑碱的抗病毒核苷类似物 | |
CN1504196A (zh) | 甘草甜素及其衍生物用于mcp-1生成抑制剂的用途 | |
CN1264541C (zh) | 抗乙型肝炎病毒活性增高的龙芽草属植物提取物的制备方法、药物和食品组合物 | |
CN1486691A (zh) | 波棱素化合物及其制法和其药物组合物与用途 | |
CN114796233A (zh) | 积雪草酸在制备乙型肝炎治疗药物中的用途 | |
CN1623551A (zh) | 一种含活性成分阿德福韦或其盐的固体分散物及其制备方法 | |
CN1775217A (zh) | 治疗乙型肝炎的药物组合物 | |
CN1197641A (zh) | 含有鞣料云实素的药物 | |
CN1431011A (zh) | 用于治疗肝炎的口服药物 | |
CN1759887A (zh) | 黏膜吸收摄取型干扰素诱生药用组合物及其制剂 | |
CN100338080C (zh) | 9-[2-(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |